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1. Introduction 
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in Western 
countries mainly affecting individuals older than 50 years. It follows an extremely variable 
course, with survival ranging from months to decades. Available treatments often induce 
remissions, though almost all patients relapse and CLL remains an incurable disease [1]. 
However, recent advances in molecular biology have enabled us to better understand the 
disease physiopathology and together with the development of new therapeutic agents have 
made the management of the disease more rational and more effective. 
2. Epidemiology 
The annual incidence of CLL varies with the age and sex structure of the population. 
Whereas in the USA it has been estimated at 3.5 per 100,000 (males 5.0: females 2.5) [2], in 
the UK estimates of 6.15 per 100,000 have been reported [3]. However, since in a majority of 
patients diagnosis is established because of an incidental blood count performed for 
irrelevant reasons and because of increasing life expectancies, the prevalence should 
augment in the future. The median age for diagnosis is 70 for males and 74 for females. 
Caucasian populations have a clearly higher incidence when compared to Japanese and 
Chinese population, even among patients having migrated to the USA, which suggests that 
genetic influences are stronger than environmental factors in the pathogenesis of the 
disease. The nature of this genetic predisposition remains unknown as yet.  
CLL may rarely occur in families [4, 5]. First-degree relatives of patients are three times 
more likely also to have CLL or another lymphoid neoplasm than the general population [6]. 
Using a four color flow-cytometric assay, Rawstron et al discovered that 3.5% of normal 
individuals over the age of 40 have a population of monoclonal lymphocytes (MBL) with the 
immune phenotypic characteristics of CLL cells in their blood at levels below the 3.5 x 109/L 
[7], and that in first degree relatives of patients with familial CLL the prevalence of such 
cells is between 13.5% and 18% [8, 9]. The relationship of this subclinical CLL with the full 
blown disease is a matter of intense investigation in several laboratories. MBL has been 
proposed as a precursor state of CLL, since MBL clones often carry typical CLL genetic 
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lesions and may represent pre-malignant cells. In approximately 2% of the cases, MBL 
progresses to CLL, and there is evidence that CLL is generally preceded by MBL [10, 11]. 
3. Selected topics in CLL pathogenesis 
Clinical course of CLL is variable. Recently, progress has been made in the identification of 
biological markers that could predict disease progression. Particularly, the expression of 
unmutated Ig genes, some cytogenetic abnormalities like 17p and 11q deletions and the 
expression of the zeta-associated protein 70 (ZAP-70) are associated to a poor prognosis. A 
major scientific goal is to find a biomolecular explanation for CLL prognosis heterogeneity that 
can provide clues in the understanding of disease etiology and pathogenic mechanisms which 
favor the onset of the disease, as well as its progression and evolution into aggressive variants 
(Richter’s lymphoma or prolymphocytoid leukemia) [12]. Given the important advances 
operated during recent years in CLL understanding, a full review of these topics is not possible 
within the space confines of this article. Hence, we will concentrate in 3 major topics: the genetic 
abnormalities, the B cell receptor and the balance between proliferation and apoptosis. 
3.1 Genetic abnormalities 
The nature of genetic predisposition for CLL remains unknown. None of the reported 
genetic aberrations is constant and it is presently unclear whether they constitute initial 
events or occur during evolution. In contrast with what is observed in other B cell 
malignancies, which typically exhibit balanced chromosomal translocations, in CLL the 
most frequent abnormalities are mutations, deletions or trisomies. Reciprocal balanced 
chromosomal translocations involving the heavy and light chain are very rare in CLL as 
compared to B-NHL [13, 14, 15], and aberrant somatic hypermutation, frequently present in 
DLBCL, is not observed in CLL [16]. This is consistent with the concept that CLL B-cells 
have non-active mechanisms involved in Ig class switch recombination and somatic 
hypermutation [15]. Thus, the transformation of the CLL precursor is likely to occur after 
the antigen-driven B-cell maturation. In the case of hairy cell leukemia, which correspond to 
an antigen-experienced post-GC B cells [15, 17], there is also a lack of reciprocal balanced 
chromosome translocations [18, 19]. Overall, these tumor malignancies form a group of B-
cell tumors that originate from the transformation of antigen-experienced B cells. 
Progress in cytogenetic techniques and the advent of fluorescence in situ hybridization 
(FISH) allowed important progress in this field. Döhner et al demonstrated in a series of 325 
CLL patients that chromosomal aberrations can be detected in 82% of cases [13]. In these 
conditions, 13q deletions are observed in 55% of patients, followed by trisomy 12 (18%) and 
the 11q deletion (16%). A deletion on chromosome 17p including a monoallelic deletion of 
TP53 tumor suppressor gene, and very frequently mutations in the remaining allele [20] is 
less frequently seen (7%) 
Deletions in 11q22-q23, typically involve the ataxia telangiectasia (ATM) gene [20] which 
causes a genomic instability that prevent correct DNA-damage reparation, allow the 
accumulation of mutations and thus may contribute to CLL pathogenesis. Interestingly, the 
presence of a 17p or 11q deletion is associated with poor prognosis and predominates 
among advanced stages of the disease and among patients displaying unmutated VH genes, 
whereas the 13q deletion or a normal karyotype are associated with good prognosis, early 
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disease and mutated VH genes. The genetic lesions associated with deletions of the short 
arm of chromosome 17 (del17p13) encoding the p53 tumor suppressor gene and the long 
arm of chromosome 11 (del11q23) encoding the ataxia telangectasia mutated (ATM), a 
kinase that regulates p53 gene, result in a loss of function of the p53 gene. p53 is an anti-
oncogene which, when strand breaks occur in DNA, triggers apoptosis or cell-cycle arrest. 
By controlling the repair or elimination of cells with damaged DNA, p53 maintains the 
integrity of the genome and prevents clonal progression. Many cytotoxic drugs require this 
pathway to be intact for them to be effective. Defects on this pathway constitute the 
strongest independent predictor for resistance to standard therapy [21, 22]. 
The pathogenic implications of trisomy 12 in CLL remain unresolved [23]. It is proposed 
that a putative proto-oncogen (CLLU1) may have an elevated gene dosage due to trisomy. 
The most frequent chromosomal abnormality in CLL is deletion of 13q14, being monoallelic 
in 76% of cases, and biallelic in 24% [13, 14, 24]. This deletion, also detected in MBL [11] 
occurs at a much lower frequency in multiple myeloma, DLBCL, mature T-cell lymphomas, 
and in several solid tumors [25-29]. A minimal deleted region (MDR) has been defined in a 
large number of CLL cases with monoallelic 13q14 deletion. This region contains the long 
non-coding RNA deleted in leukemia (DLEU)-2, and the first exon of the DLEU1 gene [30, 
31]. Two microRNAs (miR-15a and miR-16-1) were present within intron 4 of DLEU2 [32, 
33] and are expressed by using DLEU2 promoter region. It has been also reported that 
downregulation of DLEU2 and miR-15a/16-1 expression in CLL cases without 13q14 
deletion [32], could be explained by suppressive epigenetic mechanisms [34]. Overall, the 
available data suggested that DLEU2 and/or miR-15a/16-1 are candidate tumor suppressor 
genes. In vitro assays were performed by introducing DLEU2 mRNA into a 13q14-
homozygous deleted cell, but failed to produce any effects on cell death or proliferation [35]. 
Micro-RNAs (miRNAs) play an important role in the regulation of gene expression. Using a 
microarray methodology, Calin et al demonstrated significant differences in miRNA 
expression between CLL B cells and normal CD5+ cells. Particularly, they could substantiate 
the absence of two miRNA (miR15 and miR16) associated to a mutated profile of Ig genes 
and with deletions in the 13q14 region [36]. Fulci et al [37] also found an overexpression of 
miR-150, miR-223 and miR-29b, and miR-29c in the IgVH mutated CLL compared to the 
IgVH unmutated cases. Marton et al confirmed these findings and found a significant 
downexpression of MiRs 181, let-7a and MiR 22 [38]. 
By using biostatistical algorithms it was possible to identify miR-15a/16-1 binding sites in a 
number of mRNAs encoding gene products involved in regulating proliferation and 
apoptosis [37-44]. In summary, miR-15a/16-1 are clearly involved in critical cellular 
processes, and their disruption may contribute to lymphomagenesis. 
Two transgenic mice were developed in order to analyze the human 13q14-MDR region. The 
first model mimicked the MDR, and the second contained a deletion of miR-15a/16-1. Both 
mouse lines developed mostly indolent clonal lymphoproliferative diseases with low 
penetrance. 
Interestingly, the IGVH-CDR3 expressed by clonal lymphoproliferative B-cells were highly 
similar (BCR stereotypy), suggesting that an antigen-driven process could be involved in the 
clonal proliferation of specific tumor cell precursors.  
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Transgenic mice overexpressing the TCL1 proto-oncogene develop lymphoproliferations 
similar to those arising in MDR and miR-15a/16-1-deleted mice [45, 46]. TCL1 mRNA 
expression is upregulated in most human CLL cases but the underlying mechanism is not 
known as yet [47, 48]. 
In summary, the DLEU2/miR-15a/16-1 tumor suppressor locus plays a role in regulating 
the expansion of the mature B-cell pool, by preventing the entry into G0/G1-S transition. 
The impairment of this cell cycle control in MDR-deleted cells may allow them to proliferate 
after BCR stimulation by foreign or self antigens.  
In these conditions, a model for the pathogenesis of CLL with 13q14 deletion based on the 
presumptive cellular origin of the tumor cell precursor can be proposed.  
The putative CLL precursor could be an antigen-experienced CD27+ B cell, expanded either 
in the course of a GC B-cell T-dependent or T-independent response by chronic antigen-
stimulation through extrinsic or autoantigens. Over time, genetic abnormalities may 
accumulate in the genome of these chronically stimulated B cells and lead to the outgrow of 
clones with MBL phenotype. Additional genetic aberrations may be incorporated in the 
course of proliferation leading to the oncogenic hit that transform these precursor in bona 
fide CLL cells. 
Despite clinical and molecular differences, global gene expression profile analysis 
demonstrated that all CLL show a homogeneous gene expression profile irrespective of their 
IgV mutational status and differing from other lymphoid cancers, which suggests a common 
cellular precursor [49, 50]. These analyses in addition revealed that the gene expression 
profile of all CLL is related to that of antigen-experienced B cells, which in the human are 
defined by expression of the CD27 cell surface antigen, and that include classical memory B 
cells and marginal zone B cells which can be somatically mutated or unmutated [51, 52]. 
However, despite sharing a common signature CLLs expressing mutated and unmutated 
IgVH genes differentially express more than 100 genes. Among these, over-expression of 
genes encoding zeta-chain-associated protein 70 (ZAP-70), lipoprotein lipase (LPL), BCL-7a, 
dystrophin and gravin are observed in the aggressive unmutated cases, while stable 
mutated cases over-express Wnt3, CTLA-4, NRIP1 nuclear receptor gene, ADAM29 and the 
transcription factor TCF7  [53]. These results suggest that indolent mutated and aggressive 
unmutated CLLs constitute two variants of the same disease. The reasons accounting for 
these striking differences in clinical outcomes of these two variants remain unsolved.  
Genome-wide association studies have detected some loci influencing CLL risk [54, 55] and 
a recent whole-genome sequencing study identified 46 somatic mutations plus four 
recurrent mutations in the genes NOTCH1, XPO1, MYD88 and KLHL6 [56]. 
3.2 B-cell receptor (BCR) characteristics in CLL 
Three main phenotypic features define B-CLL: the predominant population shares B-cell 
markers (CD19, CD21, and CD23) with the CD5 antigen, in the absence of other pan-T-cell 
markers; the B cells are monoclonal with regard to expression of either k or light chains 
and the B cells characteristically express surface immunoglobulin (slg), CD79b, CD20 and 
CD22 with low density. These characteristics are generally adequate for a precise diagnosis 
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of CLL, and they also distinguish CLL from other disorders such as prolymphocytic 
leukemia, hairy-cell leukemia, mantle-cell lymphoma and other lymphomas that can mimic 
CLL [57-59]. 
The BCR is a multimeric complex formed by the assembly of surface immunoglobulin (SIg) 
and the noncovalently bound heterodimer Ig┙/Ig┚ (CD79a/CD79b). Low expression of the 
BCR is the hallmark of the B-CLL lymphocyte [60, 61]. 
The mechanisms accounting for poor expression of the BCR in CLL remain elusive. There is 
no evidence of genetic defects in the BCR components [62, 63] and in contrast with their 
poor expression at the membrane level, transcription and intra-cellular synthesis of BCR 
components are normal [63, 64]. However, they cannot be assembled and transported from 
the endoplasmic reticulum to the cell surface because of a folding and glycosolation defect 
of the mu and CD79a chains though not of the CD79b chain. The poor expression of the 
CD22 molecule in B-CLL cells, was also found to result as a consequence of a folding defect 
occurring in its ┙ chain [65]. 
One unsolved issue concerns the role of the clonal B-cell receptor (BCR) in disease 
progression. Despite the fact that low expression of the BCR correlates with reduced 
induction of protein tyrosine kinase activity and defective intracellular calcium mobilization 
and tyrosine phosphorylation [66] this receptor conserves the capacity of antigen 
recognition and signaling, controlling thereby key behaviors of tumor cell, like proliferation 
and cell survival.  Individual patients have different responses to IgM ligation which are 
related to VH gene status. In a majority of cases, CLL cells expressing unmutated IgVH 
genes showed a better response than cases expressing mutated IgVH genes [67]. 
The vast majority of B-CLL cells express a CD5+ and IgM/IgD mantle zone-like phenotype 
of naive cells, which, in normal conditions express unmutated Ig genes [68]. However, 50%-
70% of CLL harbor somatic mutations of IgVH genes [69] as if they had matured in a 
lymphoid follicle. Interestingly, the presence or absence of somatic mutations is associated 
with the use of particular IgVH genes. For instance, alleles of the V1-69 [70] gene and the V4-
39 gene display an unmutated profile [71]. 
Two reports demonstrated that the clinical behavior of CLL is related to the mutational 
status of immunoglobulin (Ig) genes [72, 73]. CLLs with mutated Ig genes display a good 
prognosis and those with unmutated Ig genes a poor prognosis. This observation has been 
extensively confirmed [74, 75] and it is well established that the mutational status of Ig genes 
constitutes a strong prognostic indicator in CLL. The mutational profile of Ig genes 
delineates prognostic groups within all Binet’s stages [76]. Interestingly, the rearrangement 
of a specific IgVH gene, V3-21, has been associated with poor prognosis whether mutated or 
not [77]. 
Evidence for the notion that CLL is a tumor of antigen experienced B cells comes from the 
structure of the rearranged IgV genes. Analyses of large panels of CLL cases revealed that 
certain IgV gene family members, which could be hypermutated or unmutated, were 
expressed significantly more frequently in CLL than would be expected from their 
expression in the IgV gene repertoire of normal B cells [69]. Of note, it was confirmed that 
the CLL-characteristic IgV gene repertoire does not simply reflect its known restriction 
during the aging process. These findings suggest that all CLL express restricted sets of 
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BCRs, and led to the conclusion that many if not all CLL originate from the malignant 
transformation of B cells previously stimulated by antigen. This concept was virtually 
proven to be true when it emerged that more than 20% of CLL cases from unrelated patients 
can have extremely similar, sometimes even identical antigen receptors [78–82]. The use of 
almost identical BCRs in 1.3% of CLLs provided compelling evidence that the Igs expressed 
by CLL B cells are highly selected. It would be statistically unexpected to find 2 cases with 
such similar BCRs in 1 million patients [83]. This finding, known as BCR ‘stereotypy’, occurs 
at various levels, including IgV gene usage, VD-J junctional regions (heavy chain 
complementarity determining region-3; CDR3), and combination of certain heavy chain 
CDR3s with light chain CDR3s [84].  
These results strongly suggest that a common antigen epitope is recognized by these highly 
homologous molecules. Concerning the epitope recognized, it has been shown that 
unmutated CLL cells express highly polyreactive antibodies while most mutated ones do 
not [85, 86]. Indeed, ‘CLL antigens’ have recently been identified which represent 
autoantigens derived from cells normally destined for apoptosis; some of the recognized 
epitopes appear to be highly similar to microbial antigens [87–89]. While signaling through 
the BCR, either in a tonic or antigen-mediated fashion, is generally assumed to play a role in 
the pathogenesis of B-cell lymphomas with few exceptions (i.e. Hodgkin lymphoma which 
expresses ‘crippled’ BCRs) [90], the BCR stereotypy unique for CLL demonstrate that 
antigen as such seems to have a decisive role in the etiology of this disease. 
Results from microarray and flow cytometric studies have revealed the unexpected 
expression among tumoral CLL cells, of molecules involved in cell activation like the zeta 
associated protein 70 (ZAP-70), the CD38 molecule, the activation induced cytidine 
deaminase (AID) and the lipoprotein lipase (LPL). 
Thus, high levels of ZAP-70, usually found in T and NK cells but not in normal circulating B 
cells, are detected in the majority of unmutated CLLs [50]. CLL B cells that express ZAP-70 
are more likely to respond to IgM cross-linking with increased tyrosine phosphorylation 
and calcium flux than ZAP-70 negative CLL B cells. This effect could occur because 
following BCR ligation ZAP-70 undergoes tyrosine phosphorylation and becomes 
associated with surface immunoglobulin and CD79b [91] and/or because ZAP-70 mediates 
inhibition events that terminate the signalling response [92] and/or because ZAP-70 
expression is associated with advantageous survival responses [93]. Altogether, expression 
of ZAP-70 in CLL allows more effective IgM signaling in CLL B cells, which might be 
responsible for a more aggressive course.  The apparently anomalous expression of ZAP-70 
in CLL cells is not completely explained. Recent data revealed that ZAP-70 is expressed at 
initial stages of B cell maturation and in other B-cell malignancies, like acute lymphoblatic 
leukemia [94]. 
Another unexpected molecule expressed by a subset of CLL B cells is CD38. This molecule is 
present during B-cell development when cell-to-cell interactions are crucial to development 
[95]. Examples include an early bone marrow precursor cell, cells in the germinal center and 
plasma cells [96]. In CLL, expression of this molecule predominates among those with 
unmutated IgVH genes and is associated to poor prognosis [97]. 
Interestingly, the activation induced cytidine deaminase (AID), a B cell-restricted enzyme, 
required for somatic mutation and isotype switching, is upregulated in unmutated CLL cells 
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[98-100]. While there is evidence that AID expression could be confined to a small 
proportion of the clone [101], it appears to be functional, since unmutated CLL cases can 
generate isotype-switched transcripts and proteins and mutations in the pre-switch µ region 
[98]. Upregulation of AID may be associated with loss of target specificity resulting in 
mutations in non-immunoglobulin genes such as BCL-6, MYC, PAX-5 and RHOH which are 
associated with more aggressive disease [102, 103]. 
In a previous work from our group, we reported that expression of the lipoprotein lipase 
(LPL) gene at the RNA level was clearly associated to an unmutated profile of Ig genes and 
a clinical poor outcome in CLL [104]. LPL is normally produced by parenchymal cells in 
several tissues, with the largest expression found in adipose tissue, cardiac and skeletal 
muscle and lactating mammary gland. In addition, LPL can augment interaction between 
cells where it has been shown to form a bridge between monocyte and endothelial cell 
surface heparan sulfate-proteoglycans. However, LPL expression has never been previously 
reported in the case of normal B cells. For this reason, its infidel expression in CLL B cells, 
constitutes a suitable marker to study disease prognosis.  
3.3 The balance between proliferation and apoptosis in CLL 
CLL can be defined as a low-grade B-cell tumor with antigen experienced monoclonal CD5+ 
B cells that, having escaped programmed cell death and undergone cell cycle arrest in the 
G0/G1 phase [105], relentlessly accumulate in lymphoid organs (lymph nodes, spleen and 
bone marrow) and circulate into the peripheral blood. This leukemic B cell accumulation 
results from a complex balance between activation of cell proliferation and inhibition of 
apoptotic death. Interestingly, circulating CLL B-lymphocytes are quiescent cells in the 
G0/G1 phase of cell cycle. Thus, CLL B cells are characterized by high expression of the 
anti-apoptotic BCL-2 protein in the absence of specific translocations and by high expression 
of the p27kip protein, which blocks progression into cell cycle. Given the key role of this 
protein in cell cycle progression, its over-expression in CLL cells could account for the 
accumulation of B cells in early phases of the cell cycle. In addition, other members of the 
BCL-2 family such as anti-apoptotic proteins BCL-XL, BAG-1 and MCL-1 are over-
expressed, while pro-apoptotic proteins like BAX and BCL-XS are under-expressed [106, 
107]. Taken together, these data suggest that CLL is a disease resulting from accumulation 
rather than from proliferation.  
As opposed to in vivo results, apoptosis occurs after in vitro culture, which suggests a role of 
the microenvironment in CLL cell survival [108, 109]. In agreement with this hypothesis are 
results indicating that apoptosis in vitro is prevented by exposure to interleukin-4 (IL-4) as 
well as by stimulation via surface CD40 [109].  
Most scientific work focusing in CLL uses circulating leukemic cell samples obtained from 
peripheral blood. However, it is reasonably to propose that the most important 
physiopathological events presumably occur in tissues [110] where leukemic cells: (i) are 
activated by antigen - BCR stimulation; (ii) are regulated and expanded by T-cell signals; 
(iii) proliferate in pseudofollicular centers, and (iv) interact with stromal cells that favor cell 
accumulation. 
In vivo, inhibition of apoptosis may occur in pseudo-follicles observed in the lymph nodes 
and in the cell clusters described in the bone marrow [111]. These pseudo-follicles include in 
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close contact with proliferating B cells increased numbers of CD4-T cells expressing CD40L. 
These activated CD4-T cells could be recruited by tumor B cells since they constitutively 
express the T cell-attracting chemokines CCL17 and 22 [112, 113]. CLL lymphocyte 
localization depends on sequential engagement of adhesion molecules and chemokine 
receptors (CXCR3, CXCR4, and CXCR5) that may direct leukemic cell chemotaxis in vitro 
[110]. In addition, CLL cell apoptosis can be prevented by interactions with stromal and 
nurse-like cells [114]. 
The interaction between CD38 and CD31 also favors the survival of leukemic cells [115]. 
Furthermore, interleukin-4 and CXCL13/SDF-1 might expand CLL clones by up-regulating 
the expression of anti-apoptotic genes including BCL2, SURVIVIN, and MCL1. These findings 
suggest that different subsets of T-cell may influence malignant B-cell to proliferate and that 
different stromal and accessory cells may favors prolonged survival and accumulation [110].  
Toll-like receptors (TLR), concomitantly with the BCR, may also play a role in the co-
stimulation of CLL cells [116]. Antigen stimulation and inflammation signals could be 
involved in the initial steps and in the progression of different B-cell chronic lymphoid 
malignancies. It has been recently reported that an inflammatory microenvironment, 
including TLR signaling, is at the basis of the CLL cell survival support provided by stromal 
accessory cells. CCL2 was reported to be induced in monocytes by the presence of CLL cells 
in vitro and increased levels of CCL2 were also detected in serum from CLL patients [117]. 
CCL2 binds to the chemokine receptors CCR2 and CCR4 [118], has chemotactic activity for 
monocytes and basophils, recruits memory T cells and dendritic cells to the sites of 
inflammation, and has also been implicated in the migration and localization of follicular 
lymphoma cells [119]. Taken together, these results could be in agreement with a model of 
selective survival of clones which would receive survival signals in these particular sites.  
By using a non-radioactive, stable isotopic labelling method to measure CLL kinetics, 
Messmer et al showed that B-CLL is not a static process that results simply from 
accumulation of long-lived lymphocytes, but a disease where a dynamic process in which 
cells proliferate and die, often at appreciable levels ranging from 0.08% to 1.7% of the clone 
[120]. This finding is in conflict with the dogma that CLL is a disease characterized almost 
exclusively by cell accumulation due to a defect in apoptosis. It is clear that most, if not all, 
proliferative events occur in the tissues where leukemic cells are able to exploit 
microenvironment interactions in order to avoid apoptosis and acquire tumoral growing 
conditions. This mechanism may compensate for the clonal decrease that could occur in the 
periphery by apoptosis and depending on its importance could play a major role in the 
regulation of the tumor burden.  
4. Conclusions 
Considerable progress has been achieved in recent years in the comprehension of CLL 
pathogenesis. We are starting to understand which genes, molecules and accessory cell 
subsets are involved in CLL cell/microenvironment interactions and what roles they play. 
However, we still have to elucidate the molecular mechanisms through which these cells 
promote the accumulation of leukemic cells. Particularly, the role of cytokines, chemokines 
and chemokine receptors in shaping a supportive microenvironment is still poorly 
understood as well as the respective role of stromal cells and different T cell subsets.  
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The BCR appears to play a major role in CLL pathogenesis. However, we cannot provide a 
plausible explanation of the mechanisms leading to its poor expression at the membrane 
level and why the mutational profile of Ig genes plays such a major role in CLL prognosis. 
Considerable progress has been achieved in the identification of the genetic lesions involved 
in CLL, particularly in the case of the 13q deletion, for which transgenic mouse models have 
provided important information on its role in CLL pathogenesis. However, the definitive 
role of these genetic lesions in CLL pathogenesis remains elusive as yet. 
Space dictates that this review be limited in scope. We are aware that there are many other 
aspects of this fascinating disease which we have not covered.  
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